|
1）Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2 alphaB gene associated with myeloblastic leukemias. Blood. 1999; 93(6): 1817-24
|
|
|
|
2）Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999; 23(2): 166-75
|
|
|
|
|
3）Sanada M, Suzuki T, Shih LY, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009; 460(7257): 904-8
|
|
|
|
|
|
4）Muramatsu H, Makishima H, Jankowska AM, et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood. 2010; 115(10): 1969-75
|
|
|
|
|
|
5）Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet. 2010; 42(9): 794-800
|
|
|
|
|
|
6）Gomez-Segui I, Makishima H, Jerez A, et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia. 2013; 27(9): 1943-6
|
|
|
|
|
|
7）Aoki Y, Niihori T, Banjo T, et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet. 2013; 93(1): 173-80
|
|
|
|
|
|
8）Schinzel A, Giedion A. A syndrome of severe midface retraction, multiple skull anomalies, clubfeet, and cardiac and renal malformations in sibs. Am J Med Genet. 1978; 1(4): 361-75
|
|
|
|
|
|
9）Rodriguez JI, Jimenez-Heffernan JA, Leal J. Schinzel-Giedion syndrome: autopsy report and additional clinical manifestations. Am J Med Genet. 1994; 53(4): 374-7
|
|
|
|
|
|
10）Hoischen A, van Bon BW, Gilissen C, et al. De novo mutations of SETBP1 cause Schinzel-Giedion syndrome. Nat Genet. 2010; 42(6): 483-5
|
|
|
|
|
|
11）Minakuchi M, Kakazu N, Gorrin-Rivas MJ, et al. Identification and characterization of SEB, a novel protein that binds to the acute undifferentiated leukemia-associated protein SET. Eur J Biochem. 2001; 268(5): 1340-51
|
|
|
|
|
|
12）Panagopoulos I, Kerndrup G, Carlsen N, et al. Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12). Br J Haematol. 2007; 136(2): 294-6
|
|
|
|
|
|
13）Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell. 2008; 3(2): 207-20
|
|
|
|
|
|
14）Cristobal I, Blanco FJ, Garcia-Orti L, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood. 2010; 115(3): 615-25
|
|
|
|
|
|
15）Piazza R, Valletta S, Winkelmann N, et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet. 2013; 45(1): 18-24
|
|
|
|
|
|
16）Sakaguchi H, Okuno Y, Muramatsu H, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 2013; 45(8): 937-41
|
|
|
|
|
|
17）Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013; 45(8): 942-6
|
|
|
|
|
|
18）Damm F, Itzykson R, Kosmider O, et al. SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias. Leukemia. 2013; 27(6): 1401-3
|
|
|
|
|
|
19）Laborde RR, Patnaik MM, Lasho TL, et al. SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia (CMML): independent prognostic impact in CMML. Leukemia. 2013; 27(10): 2100-2
|
|
|
|
|
|
20）Pardanani A, Lasho TL, Laborde RR, et al. CS F3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013; 27(9): 1870-3
|
|
|
|
|
|
21）Meggendorfer M, Bacher U, Alpermann T, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013; 27(9): 1852-60
|
|
|
|
|
|
22）Thol F, Josef Suchanek K, Koenecke C, et al. SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia. 2013; 27(10): 2072-5
|
|
|
|
|
|
23）Fernandez-Mercado M, Pellagatti A, Di Genua C, et al. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression. Br J Haematol. 2013; 163(2): 235-9
|
|
|
|
|
|
24）Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011; 117(21): e198-206
|
|
|
|
|
|
25）Oakley K, Han Y, Vishwakarma BA, et al. Setbp1 promotes the self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10. Blood. 2012; 119(25): 6099-108
|
|
|
|
|
|
26）Cohen SB, Zheng G, Heyman HC, et al. Heterodimers of the SnoN and Ski oncoproteins form preferentially over homodimers and are more potent transforming agents. Nucleic Acids Res. 1999; 27(4): 1006-14
|
|
|
|
|